Research Article
Characterization of Selected Metabolic and Immunologic Markers Following Exclusive Enteral Nutrition of Pediatric Crohn’s Disease Patients
Viral Brahmbhatt1*, Ivan Montoliu1, Nabil Bosco1, François-Pierre Martin1, Phillipe Guy1, Manuel Oliveira1, Stephanie Schatz2, Katharina Werkstetter2, Eduardo Schiffrin1, Berthold Koletzko2, Jalil Benyacoub1 and Sibylle Koletzko21Research and Development, NESTEC LTD, Lausanne, Switzerland
2Pediatric GI, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University of Munich, München, Germany
- Corresponding Author:
- Viral Brahmbhatt
Nestlé Research and Development Centre India Pvt. Ltd.
CP-12A, Sector-8, IMT Manesar
Gurgaon, Haryana, 122050, India
Tel: +911244195525
E-mail: Viral.Brahmbhatt@rd.nestle.com
Received Date: August 01, 2016; Accepted Date: August 27, 2016; Published Date: August 31, 2016
Citation: Brahmbhatt V, Montoliu I, Bosco N, Martin FP, Guy P, et al. (2016) Characterization of Selected Metabolic and Immunologic Markers Following Exclusive Enteral Nutrition of Pediatric Crohn’s Disease Patients. J Gastrointest Dig 6:466. doi:10.4172/2161-069X.1000466
Copyright: © 2016 Brahmbhatt V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.
Abstract
Objectives: Exclusive enteral nutrition (EEN) is one of the first-line therapeutic options for pediatric patients with active Crohn’s disease (CD). However, only sparse data exist on plasma metabolic changes from patients on EEN therapy. Thus to gain mechanistic insights, we have characterized selected markers in pediatric CD patients treated with EEN for induction of disease remission. Methods: Plasma levels of 18 cytokines and chemokines and 163 metabolites in 10 pediatric CD patients receiving 8 weeks of EEN therapy were measured. Measurements were performed at three time points: a) at baseline (V0); b) during EEN intervention at week 4 (V4) and; c) at 4 weeks after completion of EEN therapy at week 12 (V12). Results: Comparisons between V0 and V4 levels identified changes in 20 different molecules, including increases in 7 metabolites of the diacyl phosphatidylcholine (PC) class and 6 metabolites of the alkylacyl PC class. However, most of these changes were not sustained after returning to a normal diet, i.e. only 7 out of the 20 molecules with significant changes between V0 and V4 still retained significance upon comparing V0 and V12. Conclusions: The changes in the plasma levels of various phospholipids at different time-points reflect the nutritional intervention and improved health status of pediatric CD patients.
